Deutsche Bank AG Buys New Stake in Sana Biotechnology, Inc. $SANA

Key Points

• Deutsche Bank acquired 645,087 shares of Sana Biotechnology during the second quarter, worth approximately $2.25 million and representing about 0.23% of the company. Institutional investors and hedge funds collectively own 88.23% of Sana’s stock.
• Analyst sentiment is generally positive, with a consensus rating of “Moderate Buy” and an average price target of $9.33. Ratings include one Strong Buy, seven Buys, one Hold, and one Sell.
• Sana shares opened at $4.09, compared with a 52-week range of $2.61 to $6.55. The company recently reported a quarterly loss of $0.13 per share, beating estimates for a $0.15 loss.

Deutsche Bank AG bought a new stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 645,087 shares of the company's stock, valued at approximately $2,251,000. Deutsche Bank AG owned about 0.23% of Sana Biotechnology as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in the stock. AQR Capital Management LLC boosted its stake in shares of Sana Biotechnology by 49.8% during the first quarter. AQR Capital Management LLC now owns 573,146 shares of the company's stock valued at $963,000 after acquiring an additional 190,483 shares during the last quarter. Woodline Partners LP raised its stake in Sana Biotechnology by 13.1% in the 1st quarter. Woodline Partners LP now owns 780,656 shares of the company's stock valued at $1,312,000 after purchasing an additional 90,515 shares during the last quarter. Franklin Resources Inc. lifted its holdings in Sana Biotechnology by 86.8% in the 2nd quarter. Franklin Resources Inc. now owns 93,081 shares of the company's stock valued at $254,000 after purchasing an additional 43,247 shares in the last quarter. Rhumbline Advisers lifted its holdings in Sana Biotechnology by 11.6% in the 2nd quarter. Rhumbline Advisers now owns 203,283 shares of the company's stock valued at $555,000 after purchasing an additional 21,149 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new stake in shares of Sana Biotechnology during the 2nd quarter worth about $50,000. 88.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Rodman & Renshaw began coverage on shares of Sana Biotechnology in a report on Monday, May 11th. They set a "buy" rating and a $16.00 price target for the company. Weiss Ratings raised shares of Sana Biotechnology from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, July 23rd. Wall Street Zen lowered shares of Sana Biotechnology from a "hold" rating to a "sell" rating in a research report on Monday, July 20th. Bank of America decreased their target price on shares of Sana Biotechnology from $7.00 to $6.00 and set a "buy" rating on the stock in a research report on Friday, August 14th. Finally, TD Cowen raised shares of Sana Biotechnology to a "strong-buy" rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $9.33.

Sana Biotechnology Stock Down 1.7%

NASDAQ:SANA opened at $4.09 on Friday. Sana Biotechnology, Inc. has a fifty-two week low of $2.61 and a fifty-two week high of $6.55. The firm's 50 day moving average is $3.56 and its two-hundred day moving average is $3.41. The company has a market cap of $1.22 billion, a P/E ratio of -5.38 and a beta of 2.16.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.02. Research analysts forecast that Sana Biotechnology, Inc. will post -0.72 earnings per share for the current fiscal year.

Sana Biotechnology Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company's core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source